Gwenn Hansen
Company: Nurix Therapeutics
Job title: Chief Scientific Officer
Seminars:
Roundtable Discussion: Discussing the Utility of Activating or Inactivating Ligases to Strategize a Novel Class of Modulating Drugs 2:30 pm
day: Day Two
Building a DEL-Driven Discovery Pipeline for More Efficient Access to E3 Ligase Binders for Degrader Development 11:00 am
day: Day Two